ENvue Medical, Inc. 8-K

What Happened
ENvue Medical, Inc. announced that its Board approved an amendment and restatement of the company’s 2024 Long Term Incentive Plan on December 24, 2025. The Amended and Restated Plan modifies the definition of “Awards” for Israeli law purposes to expressly include restricted stock units (RSUs) and other awards that may be granted under Section 102 of Israeli tax law. The plan also incorporates non-material updates, including changes tied to the company’s name change from NanoVibronix, Inc. to ENvue Medical, Inc., and updates related to a First Amendment previously approved by stockholders on December 4, 2025. The full text of the Amended and Restated Plan is filed as Exhibit 10.1 to the Form 8-K.

Key Details

• Board approval date: December 24, 2025.
• Plan amended and restated: 2024 Long Term Incentive Plan.
• Key change: expands Awards definition for Israeli law to include RSUs and other Section 102 awards.
• Additional updates: non-material edits for the company name change and following the stockholder-approved First Amendment (Dec 4, 2025).

Why It Matters
This update affects the company’s equity compensation framework and ensures ENvue can grant awards (including RSUs) that comply with Israeli tax rules for eligible participants. For investors, the change is primarily about legal and tax compliance and how future equity awards to Israeli-based service providers or employees may be structured and taxed. The amendment could influence how the company issues and accounts for long-term incentive awards going forward.